Nektar prevails in legal battle with Lilly over broken rezpeg partnership

Nektar Therapeutics has been awarded $90 million in damages after a jury sided with the biotech, which had accused Big Pharma Eli Lilly of “botching” an analysis of their formerly partnered autoimmune drug.

Scroll to Top